SEARCH

SEARCH BY CITATION

References

  • 1
    Alter HJ. To C or not to C: these are the questions. Blood 1995; 85: 16811695.
  • 2
    Hayashi J, Yoshimura E, Kishihara Y, Yamaji K, Etoh Y, Ikematsu H, Kashiwagi S. Hepatitis C virus RNA levels determined by branched DNA probe assay correlated with levels assessed using competitive PCR. Am J Gastroenterol 1996; 91: 314318.
  • 3
    Perrillo RP. The role of liver biopsy in hepatitis C. Hepatology 1997; 26: 57S61S.
  • 4
    Poynard T, McHutchison J, Goodman Z, Ling MH, Albrecht J. Is an “a la carte” combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group. Hepatology 2000; 31: 211218.
  • 5
    Jouet P, Roudot-Thoraval F, Dhumeaux D, Metreau JM. Comparative efficacy of interferon alfa in cirrhotic and noncirrhotic patients with non-A, non-B, C hepatitis. Le Groupe Francais pour l'Etude du Traitement des Hepatites Chroniques NANB/C. Gastroenterology 1994; 106: 686690.
  • 6
    van Leeuwen DJ, Wilson L, Crowe DR. Liver biopsy in the mid-1990s: questions and answers. Semin Liver Dis 1995; 15: 340359.
  • 7
    Gebo KA, Jenckes MW, Chander G, Torbenson MS, Ghanem KG, Herlong HF, Sulkowski MS, et al. Evidence report on management of chronic hepatitis C. Web Page. Available at: “Health Care: Evidence-based Practice Subdirectory Page,” URL: www.ahrq.gov/clinic/epcix.htm.
  • 8
    McNamara RL, Bass EB, Miller MR, Segal JB, Goodman SN, Kim NL, Robinson KA, et al. Management of new onset atrial fibrillation No. 12 (Prepared by the Johns Hopkins University Evidence-based Practice Center under Contract No. 290–097–0006.) AHRQ Publication No. 01–E026. Rockville, MD: Agency for Healthcare Quality and Research; 2001.
  • 9
    Garbutt JC, West SL, Carey TS, Lohr KN, Crews FT. Pharmacological treatment of alcohol dependence: a review of the evidence. JAMA 1999; 281: 13181325.
  • 10
    Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958965.
  • 11
    Berg T, Hoffmann RM, Teuber G, Leifeld L, Lafrenz M, Baumgarten R, Spengler U, et al. Efficacy of a short-term ribavirin plus interferon alpha combination therapy followed by interferon alpha alone in previously untreated patients with chronic hepatitis C: a randomized multicenter trial. Liver 2000; 20: 427436.
  • 12
    Mangia A, Villani MR, Minerva N, Leandro G, Bacca D, Cela M, Carretta V, et al. Efficacy of 5 MU of interferon in combination with ribavirin for native patients with chronic hepatitis C virus: a randomized controlled trial. J Hepatol 2001; 34: 441446.
  • 13
    McHutchison JG, Poynard T, Pianko S, Gordon SC, Reid AE, Dienstag J, Morgan T, et al. The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. The International Hepatitis Interventional Therapy Group. Gastroenterology 2000; 119: 13171323.
  • 14
    Saracco G, Ciancio A, Olivero A, Smedile A, Roffi L, Croce G, Colletta C, et al. A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C not responding to interferon alone. Hepatology 2001; 34: 133138.
  • 15
    Lindsay KL, Trepo C, Heintges T, Shiffman ML, Gordon SC, Hoefs JC, Schiff ER, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001; 34: 395403.
  • 16
    Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, O'Grady J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343: 16661672.
  • 17
    Ascione A, De Luca M, Canestrini C, Di Costanzo GG, Raimondo G, Longo G, Manns MP, et al. Efficacy of high dose of recombinant alpha 2b interferon on long term response in chronic hepatitis C and cirrhosis: prospective randomized multicentre study. Ital J Gastroenterol Hepatol 1998; 30: 517523.
  • 18
    Kumada T, Nakana S, Takeda I, Sugiyama K, Osada T, Kiriyama S, Toyoda H, et al. Long-term administration of natural interferon-alpha in patients with chronic hepatitis-C—relationship to serum RNA concentration, HCV-RNA genotypes, histological-changes and hepatitis-C virus. J Gastroenterol Hepatol 1996; 11: 159165.
  • 19
    Payen JL, Izopet J, Galindo-Migeot V, Lauwers-Cances V, Zarski JP, Seigneurin JM, Dussaix E, et al. Better efficacy of a 12-month interferon alfa-2b retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: a multicenter, controlled, randomized trial. Le Groupe D'etude et De Traitement du Virus De L'hepatite C (Get. Vhc). Hepatology 1998; 28: 16801686.
  • 20
    Zeuzem S, Teuber G, Naumann U, Berg T, Raedle J, Hartmann S, Hopf U. Randomized, double-blind, placebo-controlled trial of interferon alfa-2a with and without amantadine as initial treatment for chronic hepatitis C. Hepatology 2000; 32: 835841.
  • 21
    Angelico M, Cepparulo M, Barlattani A, Liuti A, Gentile S, Hurtova M, Ombres D, et al. Unfavourable effects of colchicine in combination with interferon-alpha in the treatment of chronic hepatitis C. Aliment Pharmacol Ther 2000; 14: 14591467.
  • 22
    Shiffman ML, Stewart CA, Hofmann CM, Contos MJ, Luketic VA, Sterling RK, Sanyal AJ. Chronic infection with hepatitis C virus in patients with elevated or persistently normal serum alanine aminotransferase levels: comparison of hepatic histology and response to interferon therapy. J Infect Dis 2000; 182: 15951601.
  • 23
    Saracco G, Borghesio E, Mesina P, Solinas A, Spezia C, Macor F, Gallo V, et al. Prolonged treatment (2 years) with different doses (3 versus 6 Mu) of interferon alpha-2b for chronic hepatitis type C: results of a multicenter randomized trial. J Hepatol 1997; 27: 5662.
  • 24
    Lo Iacono O, Garcia-Monzon C, Almasio P, Garcia-Buey L, Craxi A, Moreno-Otero R. Soluble adhesion molecules correlate with liver inflammation and fibrosis in chronic hepatitis C treated with interferon-alpha. Aliment Pharmacol Ther 1998; 12: 10911099.
  • 25
    Villa E, Grottola A, Buttafoco P, Colantoni A, Bagni A, Ferretti I, Cremonini C, et al. High doses of alpha-interferon are required in chronic hepatitis due to coinfection with hepatitis B virus and hepatitis C virus: long term results of a prospective randomized trial. Am J Gastroenterol 2001; 96: 29732977.
  • 26
    Shiffman ML, Hofmann CM, Gabbay J, Luketic VA, Sterling RK, Sanyal AJ, Contos MJ, et al. Treatment of chronic hepatitis C in patients who failed interferon monotherapy: effects of higher doses of interferon and ribavirin combination therapy. Am J Gastroenterol 2000; 95: 29282935.
    Direct Link:
  • 27
    Di Bisceglie AM, Thompson J, Smith-Wilkaitis N, Brunt EM, Bacon BR. Combination of interferon and ribavirin in chronic hepatitis C: re-treatment of nonresponders to interferon. Hepatology 2001; 33: 704707.
  • 28
    Mangia A, Minerva N, Annese M, Leandro G, Villani MR, Santoro R, Carretta V, et al. A randomized trial of amantadine and interferon versus interferon alone as initial treatment for chronic hepatitis C. Hepatology 2001; 33: 989993.
  • 29
    Villa E, Trande P, Grottola A, Buttafoco P, Rebecchi AM, Stroffolini T, Callea F, et al. Alpha but not beta interferon is useful in chronic active hepatitis due to hepatitis C virus: a prospective, double-blind, randomized study. Dig Dis Sci 1996; 41: 12411247.
  • 30
    Heathcote EJ, Shiffman ML, Cooksley WG, Dusheiko GM, Lee SS. Balart L, Reindollar R, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000; 343: 16731680.
  • 31
    Casaril M, Stanzial AM, Tognella P, Pantalena M, Capra F, Colombari R, Corrocher R. Role of iron load on fibrogenesis in chronic hepatitis C. Hepatogastroenterology 2000; 47: 220225.
  • 32
    Fukuda Y, Nakano I, Katano Y, Toyoda H, Imoto M, Takamatsu J, Saito H, et al. Assessment and treatment of liver disease in Japanese haemophilia patients. Haemophilia 1998; 4: 595600.
  • 33
    Gabrielli GB, Capra F, Casaril M, Squarzoni S, Tognella P, Dagradi R, De Maria E, et al. Serum laminin and type III procollagen in chronic hepatitis C: diagnostic value in the assessment of disease activity and fibrosis. Clin Chim Acta 1997; 265: 2131.
  • 34
    Giannini E, Caglieris S, Ceppa P, Risso D, Lantieri PB, Testa R. Serum pro-collagen III peptide levels are related to lobular necrosis in untreated patients with chronic hepatitis C. Eur J Gastroenterol Hepatol 2001; 13: 137141.
  • 35
    Guechot J, Poupon RE, Giral P, Balkau B, Giboudeau J, Poupon R. Relationship between procollagen III aminoterminal propeptide and hyaluronan serum levels and histological fibrosis in primary biliary cirrhosis and chronic viral hepatitis C. J Hepatol 1994; 20: 388393.
  • 36
    Guechot J, Laudat A, Loria A, Serfaty L, Poupon R, Giboudeau J. Diagnostic accuracy of hyaluronan and type III procollagenamino-terminal peptide serum assays as markers of liver fibrosis in chronic viral hepatitis C evaluated by ROC curve analysis. Clin Chem 1996; 42: 558563.
  • 37
    Ikeda K, Saitoh S, Kobayashi M, Suzuki Y, Tsubota A, Suzuki F, Arase Y, et al. Distinction between chronic hepatitis and liver cirrhosis in patients with hepatitis C virus infection. Practical discriminant function using common laboratory data. Hepatol Res 2000; 18: 252266.
  • 38
    Ishibashi K, Kashiwagi T, Ito A, Tanaka Y, Nagasawa M, Toyama T, Ozaki S, et al. Changes in serum fibrogenesis markers during interferon therapy for chronic hepatitis type C. Hepatology 1996; 24: 2731.
  • 39
    Jeffers LJ, Coelho-Little ME, Cheinquer H, Vargas C, Civantos F, Alvarez L, Reddy KR, et al. Procollagen-III peptide and chronic viral C hepatitis. Am J Gastroenterol 1995; 90: 14371440.
  • 40
    Kasahara A, Hayashi N, Mochizuki K, Oshita M, Katayama K, Kato M, Masuzawa M, et al. Circulating matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as serum markers of fibrosis in patients with chronic hepatitis C: relationship to interferon response. J Hepatol 1997; 26: 574583.
  • 41
    Lichtinghagen R, Huegel O, Seifert T, Haberkorn CI, Michels D, Flemming P, Bahr M, et al. Expression of matrix metalloproteinase-2 and-9 and their inhibitors in peripheral blood cells of patients with chronic hepatitis C. Clin Chem 2000; 46: 183192.
  • 42
    Lichtinghagen R, Michels D, Haberkorn CI, Arndt B, Bahr M, Flemming P, Manns MP, et al. Matrix metalloproteinase (MMP)-2, MMP-7, and tissue inhibitor of metalloproteinase-1 are closely related to the fibroproliferative process in the liver during chronic hepatitis C. J Hepatol 2001; 34: 239247.
  • 43
    McHutchison JG, Blatt LM, de Medina M, Craig JR, Conrad A, Schiff ER, Tong MJ, et al. Measurement of serum hyaluronic acid in patients with chronic hepatitis C and its relationship to liver histology. J Gastroenterol Hepatol 2000; 15: 945951.
  • 44
    Murawaki Y, Yamada S, Ikuta Y, Kawasaki H. Clinical usefulness of serum matrix metalloproteinase-2 concentration in patients with chronic viral liver disease. J Hepatol 1999; 30: 10901098.
  • 45
    Murawaki Y, Koda M, Okamoto K, Mimura K, Kawasaki H. Diagnostic value of serum type IV collagen test in comparison with platelet count for predicting the fibrotic stage in patients with chronic hepatitis C. J Gastroenterol Hepatol 2001; 16: 777781.
  • 46
    Murawaki Y, Ikuta Y, Okamoto K, Koda M, Kawasaki H. Diagnostic value of serum markers of connective tissue turnover for predicting histological staging and grading in patients with chronic hepatitis C. J Gastroenterol 2001; 36: 399406.
  • 47
    Ninomiya T, Yoon S, Hayashi Y, Sugano M, Kumon Y, Seo Y, Shimizu K, et al. Clinical significance of serum hyaluronic acid as a fibrosis marker in chronic hepatitis C patients treated with interferon-alpha: histological evaluation by a modified histological activity index scoring system. J Gastroenterol Hepatol 1998; 13: 6874.
  • 48
    Ohashi Y. Changes of serum markers of hepatic fibrosis after interferon treatment of patients with chronic hepatitis C. Mie Med J 1998; 48: 1925.
  • 49
    Plevris JN, Haydon GH, Simpson KJ, Dawkes R, Ludlum CA, Harrison DJ, Hayes PC. Serum hyaluronan—a non-invasive test for diagnosing liver cirrhosis. Eur J Gastroenterol Hepatol 2000; 12: 11211127.
  • 50
    Ueno T, Ide T, Hashimoto O, Uchimura Y, Torimura T, Kumashiro R, Inuzuka S, et al. Long-term follow-up of interferon-treated chronic hepatitis C and serum hepatic fibrosis markers. Hepatogastroenterology 2001; 48: 11241128.
  • 51
    Verbaan H, Bondeson L, Eriksson S. Non-invasive assessment of inflammatory activity and fibrosis (grade and stage) in chronic hepatitis C infection. Scand J Gastroenterol 1997; 32: 494499.
  • 52
    Walsh KM, Fletcher A, MacSween RN, Morris AJ. Comparison of assays for N-amino terminal propeptide of type III procollagen in chronic hepatitis C by using receiver operating characteristic analysis. Eur J Gastroenterol Hepatol 1999; 11: 827831.
  • 53
    Walsh KM, Timms P, Campbell S, MacSween RN, Morris AJ. Plasma levels of matrix metalloproteinase-2 (MMP-2) and tissue inhibitors of metalloproteinases-1 and −2 (TIMP-1 and TIMP-2) as noninvasive markers of liver disease in chronic hepatitis C: comparison using ROC analysis. Dig Dis Sci 1999; 44: 624630.
  • 54
    Walsh KM, Fletcher A, MacSween RN, Morris AJ. Basement membrane peptides as markers of liver disease in chronic hepatitis C. J Hepatol 2000; 32: 325330.
  • 55
    Wong VS, Hughes V, Trull A, Wight DGD, Petrik J, Alexander GJM. Serum hyaluronic acid is a useful marker of liver fibrosis in chronic hepatitis C virus infection. J Viral Hepat 1998; 5: 187192.
  • 56
    Yamada M, Fukuda Y, Koyama Y, Nakano I, Urano F, Katano Y, Hayakawa T. Serum hyaluronic acid reflects the effect of interferon treatment on hepatic fibrosis in patients with chronic hepatitis C. J Gastroenterol Hepatol 1996; 11: 646651.
  • 57
    Yamada M, Fukuda Y, Nakano I, Katano Y, Takamatsu J, Hayakawa T. Serum hyaluronan as a marker of liver fibrosis in hemophiliacs with hepatitis C virus-associated chronic liver disease. Acta Haematol 1998; 99: 212216.
  • 58
    Anderson FH, Zeng LC, Rock NR, Yoshida EM. An assessment of the clinical utility of serum ALT and AST in chronic hepatitis C. Hepatol Res 2000; 18: 6371.
  • 59
    Assy N, Minuk GY. Serum aspartate but not alanine aminotransferase levels help to predict the histological features of chronic hepatitis C viral infections in adults. Am J Gastroenterol 2000; 95: 15451550.
    Direct Link:
  • 60
    Barbaro G, Di Lorenzo G, Soldini M, Parrotto S, Bello G, Belloni G, Grisorio B, et al. Hepatic glutathione deficiency in chronic hepatitis C: quantitative evaluation in patients who are HIV positive and HIV negative and correlations with plasmatic and lymphocytic concentrations and with the activity of liver disease. Am J Gastroenterol 1996; 91: 25692573.
  • 61
    Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte, Benhamou Y, Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001; 357: 10691075.
  • 62
    Imperiale TF, Said AT, Cummings OW, Born LJ. Need for validation of clinical decision aids: use of the AST/ALT ratio in predicting cirrhosis in chronic hepatitis C. Am J Gastroenterol 2000; 95: 23282332.
    Direct Link:
  • 63
    McCormick SE, Goodman ZD, Maydonovitch CL, Sjogren MH. Evaluation of liver histology, ALT elevation, and HCV RNA titer in patients with chronic hepatitis C. Am J Gastroenterol 1996; 91: 15161522.
  • 64
    Michielsen PP, Hauben EI, Ramon AM, VanMarck EA, Pelckmans PA. Serum aminotransferase levels and histological disease in chronic hepatitis C. Acta Gastroenterol Belg 1997; 60: 1114.
  • 65
    Park GJ-H, Lin BPC, Ngu MC, Jones DB, Katelaris PH. Aspartate aminotransferase: alanine aminotransferase ratio in chronic hepatitis C infection: is it a useful predictor of cirrhosis? J Gastroenterol Hepatol 2000; 15: 386390.
  • 66
    Sheth SG, Flamm SL, Gordon FD, Chopra S. AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol 1998; 93: 4448.
    Direct Link:
  • 67
    Stanley AJ, Haydon GH, Piris J, Jarvis LM, Hayes PC. Assessment of liver histology in patients with hepatitis-C and normal transaminiase levels. Eur J Gastroenterol Hepatol 1996; 8: 869872.
  • 68
    Puoti C, Stati T, Magrini A. Serum HCV RNA titer does not predict the severity of liver damage in HCV carriers with normal aminotransferase levels. Liver 1999; 19: 104109.
  • 69
    Bayati N, Silverman AL, Gordon SC. Serum alpha-fetoprotein levels and liver histology in patients with chronic hepatitis C. Am J Gastroenterol 1998; 93: 24522456.
    Direct Link:
  • 70
    Fortunato G, Castaldo G, Oriani G, Cerini R, Intrieri M, Molinaro E, Gentile I, et al. Multivariate discriminant function based on six biochemical markers in blood can predict the cirrhotic evolution of chronic hepatitis. Clin Chem 2001; 47: 16961700.
  • 71
    Poynard T, Bedossa P, BioulacSage P, Callard P, Chevallier M, Degott C, Deugnier Y, et al. Age and platelet count: a simple index for predicting the presence of histological lesions in patients with antibodies to hepatitis C virus. J Viral Hepat 1997; 4: 199208.
  • 72
    Choi Y, Putti T, Win K, Hu Y, Remy P, Bloom A. Correlation of viral RNA, alanine aminotransferase, and histopathology in hepatitis C virusassociated hepatitis. Mol Diagn 1999; 4: 251254.
  • 73
    Goldstein NS, Blue DE, Hankin R, Hunter S, Bayati N, Silverman AL, Gordon SC. Serum alpha-fetoprotein levels in patients with chronic hepatitis C—relationships with serum alanine aminotransferase values, histologic activity index, and hepatocyte MIB-1 scores. Am J Clin Pathol 1999; 111: 811816.
  • 74
    Jamal MM, Soni A, Quinn PG, Wheeler DE, Arora S, Johnston DE. Clinical features of hepatitis C-infected patients with persistently normal alanine transaminase levels in the Southwestern United States. Hepatology 1999; 30: 13071311.
  • 75
    Luo JC, Hwang SJ, Lai CR, Lu CL, Li CP, Tsay SH, Wu JC, et al. Relationships between serum aminotransferase levels, liver histologies and virological status in patients with chronic hepatitis C in Taiwan. J Gastroenterol Hepatol 1998; 13: 685690.
  • 76
    Ono E, Shiratori Y, Okudaira T, Imamura M, Teratani T, Kanai F, Kato N, et al. Platelet count reflects stage of chronic hepatitis C. Hepatol Res 1999; 15: 192200.
  • 77
    Yeo AET, Ghany M, Conry-Cantilena C, Melpolder JC, Kleiner DE, Shih JWK, Hoofnagle JH, et al. Stability of HCV-RNA level and its lack of correlation with disease severity in asymptomatic chronic hepatitis C virus carriers. J Viral Hepat 2001; 8: 256263.
  • 78
    Zylberberg H, Rimaniol AC, Pol S, Masson A, De Groote D, Berthelot P, Bach JF, et al. Soluble tumor necrosis factor receptors in chronic hepatitis C: a correlation with histological fibrosis and activity. J Hepatol 1999; 30: 185191.
  • 79
    Izzo F, Curley S, Maio P, Leonardi E, Imparato L, Giglio S, Cremona F, et al. Correlation of soluble interleukin-2 receptor levels with severity of chronic hepatitis-C virus liver-injury and development of hepatocellular cancer. Surgery 1996; 120: 100105.
  • 80
    Chu CW, Hwang SJ, Luo JC, Lai CR, Tsay SH, Li CP, Wu JC, et al. Clinical, virologic, and pathologic significance of elevated serum alphafetoprotein levels in patients with chronic hepatitis C. J Clin Gastroenterol 2001; 32: 240244.
  • 81
    Shima T, Tada H, Morimoto M, Nakagawa Y, Obata H, Sasaki T, Park H, et al. Serum total bile acid level as a sensitive indicator of hepatic histological improvement in chronic hepatitis C patients responding to interferon treatment. J Gastroenterol Hepatol 2000; 15: 294299.